cycloSal-pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade

Journal of Medicinal Chemistry

Volumn 42, Issue 9, 1999, Pages 1615-1624

  Meier, Chris ^a,d   Knispel, Tina ^a,d   Marquez, Victor E ^b   Siddiqui, Maqbool A ^b   De Clercq, Erik ^c   Balzarini, Jan ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2' FLUOROARADIDEOXYADENOSINE; 2' FLUORORIBO 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIDANOSINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DEAMINATION; DRUG CONFORMATION; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPOPHILICITY; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ADENOSINE DEAMINASE; AMP DEAMINASE; ANIMALS; ANTI-HIV AGENTS; CELL LINE; DIDEOXYADENOSINE; DRUG DELIVERY SYSTEMS; HIV-1; HIV-2; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; MICE; PHOSPHORIC ACID ESTERS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 0033529065     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981097r     Document Type: Article

References (56)

1. De Clercq, E. Towards improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517.
2. (a) Balzarini, J. Metabolism and Mechanism of Antiretroviral Action of Purine and Pyrimidine Derivatives. Pharm. World Sci. 1994, 16, 113-126.
3. (b) Herdewijn, P.; Balzarini, J.; De Clercq, E. 2′,3′-Dideoxynucleoside Analogues as Anti-HIV Agents. In Advances in Antiviral Drug Design; De Clercq, E., Ed.; JAI Press Inc.: Greenwich, London, 1993; Vol. 1, pp 233-318.
4. McLaren, C.; Datema, R.; Knupp, C. A.; Buroker, R. A. Didanosine. Antiviral Chem. Chemother. 1991, 2, 321-328.
5. Shelton, M. J.; O'Donell, M.; Morse, G. D. Didanosine. Ann. Pharmacother. 1992, 26, 660-670.
6. Gao, W.-Y.; Agbaria, R.; Driscoll, J. S.; Mitsuya, H. Divergent Anti-Human Immunodeficiency Virus Activity and Anabolic Phosphorylation of 2′,3′-Dideoxynucleoside Analogs in Resting and Activated Human Cells. J. Biol. Chem. 1994, 269, 12633-12638.
7. Johnson, M. A.; Ahluwalia, G.; Conelly, M. C.; Cooney, D. A.; Broder, S.; Johns, D. G.; Fridland, A. Metabolic Pathways for the Activation of the Antiretroviral Agent 2′,3′-Dideoxyadenosine in Human Lymphoid Cells. J. Biol. Chem. 1988, 263, 15354-15357.
8. Cooney, D. A.; Ahluwalia, G.; Mitsuya, J.; Fridland, A.; Johnson, M.; Hao, Z.; Dalal, M.; Balzarini, J.; Broder, S.; Johns, D. G. Initial Studies of the Cellular Pharmacology of 2′,3′-Dideoxy-adenosine, an Inhibitor of HTLV-III Infection. Biochem. Pharmacol. 1987, 36, 1765-1768.
9. Carson, D. A.; Haertle, T.; Wasson, D. B.; Richman, D. D. Biochemical Genetic Analysis of 2′,3′-Dideoxyadenosine Metabolism in Human T Lymphocytes. Biochem. Biophys. Res. Commun. 1988, 151, 788-793.
10. Hao, Z.; Cooney, D. A.; Hartman, N. R.; Perno, C. F.; Fridland, A.; DeVico, A. L.; Sarngadharan, M. G.; Broder, S.; Johns, D. G. Factors Determining the Activity of 2′,3′-Dideoxynucleosides in Suppressing Human Immunodeficiency Virus in vitro. Mol. Pharmacol. 1988, 34, 431-435.
11. McGowan, J. J.; Tomaszewski, J.; Cracock, J.; Hoth, D.; Grieshaber, C. K.; Broderand, S.; Mitsuya, H. Overview of the Preclinical Development of an Antiretroviral Drug, 2′,3′-Dideoxyadenosine. Rev. Infect. Dis. 1990, 12, S513-S521.
12. Fridland, A.; Johnson, M. A.; Cooney, D. A.; Ahluwalia, G.; Marquez, V. E.; Driscoll, J. S.; Johns, D. G. Metabolism in Human Leukocytes of Anti-HIV Dideoxypurine Nucleosides. Ann. N.Y. Acad. Sci. 1990, 616, 205-216.
13. (a) Ahluwalia, G.; Cooney, D. A.; Mitsuya, H.; Fridland, A.; Flora, K. P.; Hao, Z.; Dalal, M.; Broder, S.; Johns, D. G. Initial Studies on the Cellular Pharmacology of 2′,3′-Dideoxyinosine, an Inhibitor of HIV Infectivity. Biochem. Pharmacol. 1987, 36, 3797-3800.
14. (b) Johnson, M. A.; Fridland, A. Phosphorylation of 2′,3′-Dideoxyinosine by Cytosolic 5′-Nucleotidase of Human Lymphoid Cells. Mol. Pharmacol. 1989, 36, 291-295.
15. Stoeckler, J. D.; Bell, C. A.; Parks, R. E., Jr.; Chu, C. K.; Fox, J. J.; Ikehara, M. C(2′)-Substituted Purine Nucleoside Analogs. Interactions with Adenosine Deaminase and Purine Nucleoside Phosphorylase and Formation of Analog Nucleotides. Biochem. Pharmacol. 1982, 31, 1723-1728.
16. Also using HPLC methods, the log P values for AZT (0.05), ddA (-0.29), and ddI (-1.24) have been determined: Barchi, J. J.; Marquez, V. E.; Driscoll, J. S.; Ford, H., Jr.; Mitsuya, H.; Shirasaka, T.; Aoki, S.; Kelley, J. A. Potential Anti-AIDS Drugs. Lipophilic, Adenosine Deaminase-activated Prodrugs. J. Med. Chem. 1991, 34, 1647-1655.
17. York, J. L. Effect of the Structure of the Glycon on the Acid-Catalyzed Hydrolysis of Adenine Nucleosides. J. Org. Chem. 1981, 46, 2171-2173.
18. Chou, T.-C.; Feinberg, A.; Grant, A. J.; Vidal, P.; Reichman, U.; Watanabe, K. A.; Fox, J. J.; Philips, F. S. Pharmacological Disposition and Metabolic fate of 2′-Fluoro-5-iodo-β-D-arabino-furanosylcytosine in Mice and Rats. Cancer Res. 1981, 41, 3336-3342.
19. Masood, R.; Ahluwalia, G. S.; Cooney, D. A.; Fridland, A.; Marquez, V. E.; Driscoll, J. S.; Hao, Z.; Mitsuya, H.; Perno, C.-F.; Broder, S.; Johns, D. G. 2′-Fluoro-2′,3′-dideoxyadenosine: A Metabolically Stable Analogue of the Antiretroviral Agent 2′,3′-Dideoxyadenosine. Mol. Pharmacol. 1989, 37, 590-596.
20. It should be added that different names for the nucleoside analogues 2 and 3 could be found in the literature. Here we use the abbreviations F-ara- and F-ribo-ddA, but also the terms F-up- and F-down-ddA, F-beta- and F-alpha-ddA, and 2′,3′-dideoxy-2′-fluoroarabinosyladenine and 2′,3′-dideoxy-2′-fluorori-bosyladenine have been used. The correct names are 9-(2′,3′-dideoxy-2′-fluoro-β-D-threo-pentofuranosyl) adenine (2) and 9-(2′,3′-dideoxy-2′-fluoro-β-D-erythro-pentofuranosyl) adenine (3).
21. Marquez, V. E.; Tseng, C. K.-H.; Kelley, J. A.; Mitsuya, H.; Broder, S.; Roth, J. S.; Driscoll, J. S. 2′,3′-Dideoxy-2′-fluoro-ara-A. An Acid-Stable Purine Nucleoside Active Against Human Immunodeficiency Virus (HIV). Biochem. Pharmacol. 1987, 36, 2719-2772.
22. Marquez, V. E.; Tseng, C. K.-H.; Mitsuya, H.; Aoki, S.; Kelley, J. A.; Ford, H., Jr.; Roth, J. S.; Broder, S.; Johns, D. G.; Driscoll, J. S. Acid Stable 2′-Fluoro Purine Dideoxynucleosides as Acitve Agents Against HIV. J. Med. Chem. 1990, 33, 978-985.
23. Herdewijn, P.; Pauwels, R.; Baba, M.; Balzarini, J.; De Clercq, E. Synthesis and Anti-HIV Activity of Various 2′- and 3′-Substituted 2′,3′-Dideoxyadenosines: A Structure-Activity Analysis. J. Med. Chem. 1987, 30, 2132-2137.
24. Boyle, M. J.; Flanigan, M. E.; Ford, H.; Baseler, M.; Adelsberger, J.; Davey, R. T.; Lane, H. C. The Hu-HIV/PBL-SCID Mouse: A Modified Hu-PBL-SCID Model for the Study of HIV Pathogenesis and Therapy. J. Immunol. 1995, 154, 6212-6223.
25. Ruxrungtham, K.; Boone, E.; Ford, H.; Driscoll, J. S.; Davey, R. T.; Lane, H. C. Potent Activity of 2′-β-Fluoro-2′,3′-dideoxyadenosine Against Human Immunodeficiency Virus Type 1 Infection in Hu-PBL-SCID mice. Antimicrob. Agents Chemother. 1996, 40, 2369-2374.
26. Hitchcock, M. J. M.; Woods, D.; De Boeck, H.; Ho, H.-T. Biochemical Pharmacology of 2′-Fluoro-2′,3′-dideoxyarabinosyladenine an Inhibitor of HIV with Improved Metabolic and Chemical Stability Over 2′,3′-Dideoxyadenosine. Antiviral Chem. Chemother. 1990, 1, 319-327.
27. Tsai, C.-H.; Doong, S.-L.; Johns, D. G.; Driscoll, J. S.; Cheng, Y.-C. Effect of Anti HFV 2′-β-Fluoro-2′,3′-dideoxynucleoside Analogs of the Cellular Content of Mitochondrial DNA and on Lactate Production. Biochem. Pharmocol. 1994, 48, 1477-1481.
28. Zhang, H.; Cooney, D. A.; Sreenath, A.; Zhan, Q.; Agbaria, R.; Stowe, E. E.; Fornace, A. J., Jr.; Johns, D. G. Quantitation of Mitochondrial DNA in Human Lymphoblast by a Competitive Polymerase Chain Reaction Method: Application to the Study of Inhibitors of Mitochondrial DNA Content. Mol. Pharmacol. 1994, 46, 1063-1069.
29. Driscoll, J. S.; Mayers, D. L.; Bader, J. P.; Weislow, O. S.; Johns, D. G.; Buckheit, R. W. 2′-Fluoro-2′,3′-dideoxyadenosine (F-ddA): Activity Against Drug-Resistant Human Immunodeficiency Virus Strains and Clades A-E. Antiviral Chem. Chemother. 1997, 8, 107-111.
30. Yarchoan, R. 12th World AIDS Conference, June 28-July 3, 1998, Geneva; Abstr. No. 22281. Kelley, J. A. 12th World AIDS Conference, June 28-July 3, 1998, Geneva; Abstr. No. 42263.
31. Yarchoan, R. 12th World AIDS Conference, June 28-July 3, 1998, Geneva; Abstr. No. 22281. Kelley, J. A. 12th World AIDS Conference, June 28-July 3, 1998, Geneva; Abstr. No. 42263.
32. Marquez, V. E.; Lim, B. B.; Barchi, J. J., Jr.; Nicklaus, M. C. Conformational Studies and Anti-HIV Activity of Mono- and Difluorodideoxynucleosides. In Nucleosides and Nucleotides as Antitumor and Antiviral Agents; Chu, C. K., Baker, D. C., Eds.; Plenum Press: New York, 1993; pp 265-284.
33. (a) Two crystal structures have been published showing the anti-conformation of the glycosyl bond and a C2′-endo (S) conformation for the 2′-F-ara-configurated nucleoside analogues: Liaw, V.-C.; Gao, Y.-G.; Marquez, V. E.; Wang, A. H.-J. Molecular Structures of two new Anti-HIV Nucleoside Analogs: 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)adenine and 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)hypoxanthine. Nucleic Acids Res. 1992, 20, 459-465.
34. (b) In NMR studies, the preference of the C3′-endo (N) conformation for 2′-fluororibonucleosides has been shown with an N/S energy difference of 1.1-2.4 kJ/mol: Bergstrom, D.; Swartling, D. J. Fluorine Substituted Analogs of Nucleic Acid Components. In Fluorine Containing Molecules; Liebman, J. F., Greenberg, A., Dolbier, W. R., Eds.; VCH Publishers Inc.: New York, 1988; pp 259-308 and cited references.
35. (c) Another NMR method confirmed the preponderance of a C2′-endo-conformation of 2′-F-ara-ddU (P = 139°; 85% C2′-endo-conformation) and C3′-endo-conformation for 2′-ribo-ddU (P = 37°; 0% C2′-endo-conformation): Thibaudeau, C.; Plavec, J.; Chattopadhyaya, J. A New Generalized Karplus-Type Equation Realating Vicinal Proton-Fluorine Coupling Constants to H-C-C-F Torsion Angles. J. Org. Chem. 1998, 63, 4967-4984.
36. Meier, C. Pro-Nucleotides - Recent Advances in the Design of Efficient Tools for the Delivery of Biologically Active Nucleoside Monophosphates. Synlett 1998, 233-242.
37. (a) Meier, C. 4H-1.3.2-Benzodioxaphosphorin-2-nucleosyl-2-oxide - A New Concept for Lipophilic, Potential Prodrugs of Biologically Active Nucleoside Monophosphates. Angew. Chem. 1996, 108, 77-79; Angew. Chem., Int. Ed. Engl. 1996, 35, 70-72.
38. (a) Meier, C. 4H-1.3.2-Benzodioxaphosphorin-2-nucleosyl-2-oxide - A New Concept for Lipophilic, Potential Prodrugs of Biologically Active Nucleoside Monophosphates. Angew. Chem. 1996, 108, 77-79; Angew. Chem., Int. Ed. Engl. 1996, 35, 70-72.
39. (b) Meier, C.; Knispel, T.; Lorey, M. CycloSal-Pro-Nucleotides: The Design and Biological Evaluation of a New Class of Lipophilic Nucleotide Prodrugs. Int. Antiviral News 1997, 5, 183-186.
40. (a) Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. cycloSal-d4TMP: Synthesis and Antiviral Evaluation of a New d4TMP Delivery System. J. Med. Chem. 1998, 41, 1417-1427.
41. (b) Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. Cyclic Saligenyl Phosphotriesters of 2′,3′-Dideoxy-2′,3′-didehydrothymidine (d4T) - A New Pro-Nucleotide Approach. Bioorg. Med. Chem. Lett. 1997, 7, 99-104.
42. Meier, C.; Knispel, T.; De Clercq, E.; Balzarini, J. ADA-Bypass by Lipophilic CycloSal-ddAMP Pro-Nucleotides. A Second Example of the Efficiency of the cycloSal-Concept. Bioorg. Med. Chem. Lett. 1997, 7, 1577-1582.
43. See accompanying paper: Meier, C.; et al. cycloSal-Pronucleotides 2′,3′-Dideoxy-2′,3′-didehydroadenosine: Synthesis and Antiviral Evaluation of a Highly Efficient Nucleotide Delivery System. J. Med. Chem. 1999, 42, 1604-1614.
44. Meier, C.; De Clercq, E.; Balzarini, J. Nucleotide Delivery from cycloSaligenyl-3′-Azido-3′-Deoxythymidine Monophosphates (cycloSal-AZTMP). Eur. J. Org. Chem. 1998, 837-846.
45. (a) Using a somewhat different methodology, a P value of 0.96 was determined for AZT: Balzarini, J.; Cools, J. M.; De Clercq, E. Estimation of the Lipophilicity of Anti-HIV Nucleoside Analogues by Determination of the Partition Coefficient and Retention Time on a LiChrosphere 60 RP-8 HPLC Column. Biochem. Biophys. Res. Commun. 1989, 158, 413-422.
46. (b) Lien, E. J.; Gao, H.; Prabhakar, H. Physical Factors Contributing to the Partition Coefficient and Retention Time of 2′,3′-Dideoxynucleoside Analogues. J. Pharm. Sci. 1991, 80, 517-521.
47. Zimmermann, T. P.; Mahony, W. B.; Prus, K. L. 3′-Azido-3′-deoxythymidine, an Unusual Nucleoside Analogue that Permeates the Membrane of Human Erythrocytes and Lymphocytes by Nonfacilitated Diffusion. J. Biol. Chem. 1987, 262, 5748-5754.
48. Meier, C.; Habel, L.; Haller-Meier, F.; Lomp, A.; Herderich, M.; Klöcking, R.; Meerbach, A.; Wutzler, P. Chemistry and Anti-HSV-1 Evaluation of cycloSal-Nucleotides (cycloSal-NMP) of Acyclic Nucleoside Analogues. Antiviral Chem. Chemother. 1998, 9, in press.
49. Bloch, A.; Robins, M. J.; McCarthy, J. R., Jr. The Role of the 5′-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase. J. Med. Chem. 1967, 10, 908-912.
50. (a) Perigaud, C.; Aubertin, A.-M.; Benzaria, S.; Pelicano, H.; Giradet, J.-L.; Maury, G.; Gosselin, G.; Kirn, A.; Imbach, J.-L. Equal Inhibition of the Replication of Human Immunodeficiency Virus in Human T-Cell Culture by ddA Bis(Sate)phosphotriester and 3′-Azido-2′,3′-dideoxythymidine. Biochem. Pharmacol. 1994, 48, 11-14.
51. (b) Balzarini, J.; Kruining, J.; Wedgwood, O.; Pannecouque, C.; Aquaro, A.; Perno, C.-F.; Naesens, L.; Witrouw, M.; Heijtink, R.; De Clercq, E.; McGuigan, C. Conversion of 2′,3′-Dideoxyadenosine (ddA) and 2′,3′-Didehydro-2′,3′-dideoxyadenosine (d4A) to their Activity against Human Immunodeficiency Virus and Hepatitis B Virus. FEBS Lett. 1997, 410, 324-328.
52. Mitsuya, H.; Marquez, V. E. Unpublished results.
53. Nair, V.; Sells, T. B. Interpretation of the Roles of Adenylosuccinate Lyase and of AMP Deaminase in the Anti-HIV Activity of 2′,3′-Dideoxyadenosine and 2′,3′-Dideoxyinosine. Biochim. Biophys. Acta 1992, 1119, 201-204.
54. Balzarini, J.; Holy, A.; Jindrich, J.; Dvorakova, H.; Hao, Z.; Snoeck, R.; Herdewijn, P.; Johns, D. G.; De Clercq, E. 9-[(2RS)-3-Fluoro-2-phosphonylmethoxypropyl]derivativea of purines: A class of highly selective antiretroviral agents in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 4961-4965.
55. Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.
56. Balzarini, J.; Naesens, L.; Slachmuylders, J.; Niphuis, H.; Rosenberg, I.; Holy, A.; Schellekens, H.; De Clercq, E. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) Efficiently Inhibits Retrovirus Replication in vitro and Simian Immunodeficiency Virus Infection in Rhesus Monkeys. AIDS 1991, 5, 21-28.